Article
Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients.
British journal of clinical pharmacology - 1 Mar 2017
Gervasini Guillermo, Jara Carlos, Olier Clara, Romero Nuria, Martínez Ruth, Carrillo Juan Antonio
Abstract excerpt
AIMS: Anastrozole, an aromatase inhibitor widely used in breast cancer, has recently been indicated to be a P-glycoprotein (ABCB1) substrate. We have aimed to determine whether ABCB1 single-nucleotide polymorphisms (SNPs) can affect anastrozole plasma concentrations in these patients. In addition, we assessed the impact of SNPs in CYP19A1 and TCL1A on the development of arthralgia and cancer recurrence in our...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
